Blog
How risky is that biotech trial?
A framework to more methodically assess clinical development probability of success (POS).
How smart pharma can stop making bad R&D choices
R&D portfolio strategy is so … unstrategic. Together with Navigant’s Greg Belogolovsky, we have some ideas to fix it.
When biotechs get breakthrough therapy status, Mr. Market yawns
As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.